Tina deVries
2020
In 2020, Tina deVries earned a total compensation of $1.3M as EVP, Research Development at RVL Pharmaceuticals plc, a 13% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $210,000 |
|---|---|
| Salary | $436,154 |
| Stock Awards | $654,683 |
| Other | $7,108 |
| Total | $1,307,945 |
deVries received $654.7K in stock awards, accounting for 50% of the total pay in 2020.
deVries also received $210K in non-equity incentive plan, $436.2K in salary and $7.1K in other compensation.
Rankings
In 2020, Tina deVries' compensation ranked 7,447th out of 13,090 executives tracked by ExecPay. In other words, deVries earned more than 43.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,447 out of 13,090 | 43rd |
Division Manufacturing | 3,128 out of 5,621 | 44th |
Major group Chemicals And Allied Products | 1,261 out of 2,254 | 44th |
Industry group Drugs | 1,090 out of 1,954 | 44th |
Industry Pharmaceutical Preparations | 813 out of 1,459 | 44th |
Source: SEC filing on April 26, 2021.
deVries' colleagues
We found three more compensation records of executives who worked with Tina deVries at RVL Pharmaceuticals plc in 2020.
News
RVL Pharmaceuticals plc Former EVP, Research & Development Tina deVries' 2022 pay slips 19% to $561K
April 24, 2023
RVL Pharmaceuticals plc CEO Brian Markison's 2021 pay falls 63% to $1.4M
April 25, 2022
RVL Pharmaceuticals plc CEO Brian Markison's 2020 pay slips 12% to $3.8M
April 26, 2021
RVL Pharmaceuticals plc CEO Brian Markison's 2019 pay jumps 291% to $4.3M
April 20, 2020
RVL Pharmaceuticals plc CEO Brian Markison's 2018 pay slips 10% to $1.1M
April 26, 2019